About
Nanospectra Biosciences is a medical device company pioneering a patient-centric use of nanomedicine for selective thermal ablation. AuroLase, the company's lead product for the ablation of prostate cancer tissue, is the first and only ultra-focal tissue ablation therapy designed to maximize treatment efficacy while minimizing side effects typically associated with surgery, radiation, and traditional focal therapies. Implementing a multi-prong growth strategy, Nanospectra is focusing on clinical advancements, exclusive partnering agreements and ongoing research and development. Nanospectra's technology development has been funded to date by a series of grants, private equity investments and corporate partnerships.
Technologies
Keywords
Company Information
-
Employees 4
-
Founded 2001
-
Annual Revenue $5000000
-
Total Funding $12838596
Location
8285 El Rio Street, Houston, Texas, United States, 77054
